Drug intelligence / Profile preview

D377 + CKD-331

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**D377 + CKD-331** is a combination therapy currently being evaluated for the treatment of **primary hypercholesterolemia** and **familial hypercholesterolemia**. This drug regimen is investigational and is being studied in a randomized, double-blind, phase 3 clinical trial; patients receive oral administration of the combination daily[1]. Mechanistic details for D377 and CKD-331 are not specified in accessible literature, but the combination is under active evaluation as part of lipid-lowering therapy.

Beyond the preview

Go deeper on D377 + CKD-331.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D377 + CKD-331.

Explore the full profile